scholarly journals Real-World Three-Year Clinical Outcomes of Biolimus-Eluting Stents versus Other Contemporary Drug-Eluting Stents in Patients with Acute Myocardial Infarction Patients: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Ji Young Park ◽  
Seung-Woon Rha ◽  
Yung-Kyun Noh ◽  
Byoung Geol Choi ◽  
Ji Yeon Hong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cardiac Death ◽  
Bare Metal Stents ◽  
Target Lesion ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Cardiac Events ◽  
Total Death ◽  
Drug Eluting

Introduction. Biolimus-eluting stents (BES) are known to be superior to bare-metal stents. This study aims to evaluate the safety and efficacy of BES compared to other drug-eluting stents (DES) based on big data from the Korea Acute Myocardial Infarction Registry (KAMIR). Methods. The study analyzed a total of 9,759 acute myocardial infarction (AMI) patients who underwent percutaneous coronary intervention (PCI) with DES. Total death, cardiac death, recurrent MI, revascularization, stent thrombosis, target lesion failure (TLF, composite of cardiac death, recurrent myocardial infarction (MI), and target lesion revascularization), and major adverse cardiac events (MACE, composite of total death, recurrent MI, and revascularization) were analyzed in patients with AMI up to three years. Study populations were divided into BES (n = 2,020), everolimus-eluting stents (EES, n = 5,293), and zotarolimus-eluting stents (ZES, n = 2,446) groups. Results. To adjust baseline potential confounders, an inverse probability weighting (IPTW) analysis was performed. After IPTW, at three years, total death (7.2%, 8.6%, and 9.5%, P < 0.001 ), cardiac death (4.1%, 5.3%, and 6.6%, P < 0.001 ), recurrent MI (1.6%, 2.6%, and 3.2%, P < 0.001 ), TLF (6.5%, 8.1%, and 9.1%, P < 0.001 ), and MACE (15.8%, 17.5%, and 18.2%, P < 0.001 ) were lowest in the BES group compared with the other DES groups in AMI patients. During the 3-year clinical follow-up, the BES group showed better outcomes of MACE (hazard ratio (HR), 0.773; 95% confidence interval (CI), 0.676–0.884; P < 0.001 ), TLF (HR, 0.659; 95% CI, 0.538–0.808; P < 0.001 ), total death (HR, 0.687; 95% CI, 0.566–0.835; P < 0.001 ), and cardiac death (HR,0.593; 95% CI, 0.462–0.541; P < 0.001 ) than the EES groups. Conclusions. In this study, BES was superior to EES or ZES in reducing total death, cardiac death, TLF, and MACE in AMI patients.

AS-170: Drug-Eluting Stents Are Not Superior to Bare Metal Stents in Elderly Patients with Acute Myocardial Infarction

2009 ◽  
Vol 103 (9) ◽  
pp. 74B-75B
Author(s):  
Doo Sun Sim ◽  
Myung Ho Jeong ◽  
Youngkeun Ahn ◽  
Young Jo Kim ◽  
Sung Chull Chaee ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Elderly Patients ◽  
Bare Metal Stents ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Drug Eluting

Abstract 16776: Drug-eluting Stents in Large Coronary Vessels Improve Both Safety and Efficacy in Women Compared to Bare-metal Stents

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Louise H Bjerking ◽  
Kim W Hansen ◽  
Rikke Sørensen ◽  
Raban Jeger ◽  
Christoph Kaiser ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cardiac Death ◽  
Coronary Vessels ◽  
Bare Metal Stents ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Safety And Efficacy ◽  
Drug Eluting ◽  
Fatal Myocardial Infarction

Objectives: Drug-eluting stents (DES) are associated with lower rates of target vessel revascularization (TVR) compared with bare-metal stents (BMS), possibly with a particular benefit in women. Inferences on efficacy and safety of DES compared to BMS have been difficult to study in female subgroups as clinical trials often enroll a low proportion of women. Therefore we investigated the safety and efficacy of DES vs. BMS in women and men in a pooled analysis of two randomized stent trials. Methods: BASKET PROVE and BASKET PROVE II were all-comers trials including patients with coronary artery disease requiring at least one stent ≥ 3.0 mm. 4605 patients were randomized to DES vs. BMS and followed for 2 years with a primary endpoint of major adverse cardiac events (MACE: cardiac death, non-fatal myocardial infarction, TVR). The safety (cardiac death and myocardial infarction) and efficacy (non-myocardial infarction TVR) of DES vs. BMS in men and women with large coronary vessels were examined with adjusted Cox proportional hazard models. Results: At baseline, women presented with higher age and more hypertension and heart failure than did men. Risk factors such as smoking, prior myocardial infarction or revascularization were more frequent in men. DES reduced MACE rates at 2 years compared to BMS in both women (6.8 vs. 14.9 %, hazard ratio (HR) 0.40 (0.27-0.60)) and men (7.8 vs. 12.3 %, HR 0.61 (0.49-0.76)), although the reduction in MACE rates was more pronounced in women (p-value for interaction, 0.05). DES significantly reduced the overall rates of non-fatal myocardial infarction and cardiac death compared to BMS in women (HR 0.52 (0.28-0.99)) but not in men (HR 0.75 (0.53-1.05)). The stent-dependent difference in MACE was mainly driven by a difference in non-myocardial infarction TVR in women (2.7 vs. 8.9 %, HR 0.25 (0.14-0.44)) and men (3.8 vs. 7.6 %, HR 0.48 (0.36-0.65)). Conclusions: In patients requiring stenting of large coronary arteries we found that DES, as compared to BMS, were associated with improved safety in women, but not in men. Although, DES demonstrated superior efficacy over BMS in both genders, women benefited more than men. Our findings suggest that DES should always be the stent of choice in women - even in patients at low risk of restenosis.

Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction

2007 ◽  
Vol 70 (1) ◽  
pp. 1-8 ◽  
Author(s):  
L. Iri Kupferwasser ◽  
Allen M. Amorn ◽  
Nikhil Kapoor ◽  
Michael S. Lee ◽  
Saibal Kar ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Bare Metal Stents ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Drug Eluting

Drug-eluting stents versus bare-metal stents in acute myocardial infarction: A systematic review and meta-analysis

2011 ◽  
Vol 27 (1) ◽  
pp. 11-22 ◽  
Author(s):  
Hae Sun Suh ◽  
Hyun Jin Song ◽  
Ji Eun Choi ◽  
Eun Jin Jang ◽  
Hee Jeong Son ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Observational Studies ◽  
Bare Metal Stents ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Statistical Heterogeneity ◽  
Drug Eluting

Objectives: Recent concerns have been raised for the safety after drug-eluting stents (DES) implantation compared with the use of bare-metal stents (BMS) in patients with ST-elevation acute myocardial infarction (STEMI). The objective of this study was to estimate the relative impact of DES versus BMS on mortality, myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis (ST) in STEMI patients by performing comprehensive meta-analyses of randomized controlled trials (RCTs) and observational studies.Methods: We performed an electronic search and manual search of studies presented through September 2009, without language restrictions. An approach of “using systematic reviews” was used. Two independent reviewers extracted prespecified data from each study. A random-effects model was used to combine trials and to perform stratified analyses based on study designs and the duration of follow-up.Results: Fourteen RCTs were identified (N = 7,654). Compared with BMS, DES significantly reduced TVR (risk ratio [RR], 0.48; 95 percent confidence interval [CI], 0.41–0.56) and MI (RR, 0.77; 95 percent CI, 0.61–0.97), without increasing mortality (RR, 0.88; 95 percent CI, 0.70–1.10) and ST (RR, 0.93; 95 percent CI, 0.72–1.21). Among 35 observational studies (N = 44,849), the use of DES was associated with a significant reduction in mortality (RR, 0.85; 95 percent CI, 0.79–0.91) and TVR (RR, 0.61; 95 percent CI, 0.48–0.77). MI and ST were significantly lower in the DES group within 1-year follow-up, but there were no differences within 2 years of follow-up. There was no evidence of statistical heterogeneity and publication bias.Conclusions: These data in aggregate suggest that using DES in STEMI patients is safe and efficacious, but there are differences between RCT and observational data comparing DES and BMS.

scholarly journals Are Drug-Eluting Stents Safer and More Effective Than Bare-Metal Stents in Patients With Acute Myocardial Infarction?

2011 ◽  
Vol 52 (2) ◽  
pp. 78-83
Author(s):  
Ki Hong Lee ◽  
Youngkeun Ahn ◽  
Nam Sik Yoon ◽  
Hyun Ju Yoon ◽  
Young Joon Hong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Bare Metal Stents ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document